Nicotinamide Riboside (NR)
The NAD+ Precursor with Clinical Validation
NR (sold as Niagen) was the first commercially available NAD+ precursor with published human clinical trials. It converts to NAD+ via the NRK pathway, supporting cellular energy and repair.
NR vs NMN: The NAD+ Precursor Comparison
Both raise NAD+ effectively. The key differences are in metabolism, bioavailability, and regulatory status.
💠 Nicotinamide Riboside (NR)
- FDA GRAS status (self-affirmed)
- Converts via NRK1/NRK2 enzymes
- 250-1000mg typical daily dose
- Patented as Niagen (ChromaDex)
- Multiple published RCTs
🧬 NMN
- FDA status varies by jurisdiction
- Direct NAD+ precursor (one step closer)
- 250-500mg typical daily dose
- Multiple manufacturers
- Growing clinical evidence base
Clinical Evidence Summary
NR has the longest track record of human clinical trials among NAD+ precursors.
NAD+ Elevation (Martens 2018)
1000mg NR daily for 6 weeks raised blood NAD+ by approximately 60% in healthy older adults with no serious adverse effects.
Cardiovascular (Martens 2018)
NR supplementation showed trends toward reduced arterial stiffness and lower blood pressure in older adults with elevated systolic BP.
Neuroinflammation (Brakedal 2022)
In a Parkinson’s trial, NR increased brain NAD+ levels and was associated with mild improvements in clinical scores over 30 days.
Exercise & Muscle (Elhassan 2019)
NR supplementation in older men increased skeletal muscle NAD+ metabolites and improved some markers of mitochondrial function.
Dosing & Practical Considerations
This page summarizes published research and does not constitute medical advice. Consult a qualified healthcare provider before starting any supplement regimen.